Third-party testing through peptide testing labs can verify some of these parameters, but it adds cost and complexity
But combining peptides requires careful dosing adjustments and monitoring to prevent excessive inflammatory responses or other adverse effects
In a smaller cohort of patients with more severe CD phenotypes, including 17% with perianal involvement and 24% with penetrating or fistulizing disease, numerical reductions across outcomes were observed in the GLP-1RA group, but these differences did not reach statistical significance (104)
Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service
Once you reach your target dose, clinical outcomes match or exceed those of patients who began at higher concentrationsbut with significantly better real-world adherence because you tolerated the journey to that dose
Some worry these drugs bypass deeper issues